# Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

> **NCT06182085** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PRInnovation GmbH** · enrollment: 304 (actual)

## Conditions studied

- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer's Disease, Early Onset

## Interventions

- **DRUG:** PRI-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06182085
- **Lead sponsor:** PRInnovation GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182085, "Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06182085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*